Posted by Michael Wonder on 13 Jun 2020
Antimicrobials benefited from expedited FDA programs more than other drugs
12 June 2020 - Amid concerns over the need for more antimicrobials, a new analysis finds these medicines benefited more often from expedited regulatory programs than other types of drugs over the last 35 years, suggesting the Food and Drug Administration is not a roadblock to development.
To wit, 61% of 178 antimicrobials approved between 1984 and 2018 were assessed by the FDA under one or more expedited review programs, while 54% of 887 other medicines were evaluated as part of the same programs during that time.
